中国P站

Drug interaction; Proton pump inhibitors; Antiplatelet therapy; Clopidogrel metabolism; Cardiovascular outcomes; Cyp2c19 inhibition; Real-world study; Dual antiplatelet therapy; Drug safety; Clinical pharmacology

Introduction

In the management of cardiovascular disease, dual antiplatelet therapy (DAPT)—typically combining aspirin with clopidogrel—is a cornerstone in preventing thrombotic complications following percutaneous coronary interventions (PCI) and acute coronary syndromes (ACS). Simultaneously, proton pump inhibitors (PPIs) are frequently prescribed to these patients to mitigate the risk of gastrointestinal bleeding, a common side effect of antiplatelet therapy [1-5]. However, concerns have been raised about a potential drug–drug interaction between clopidogrel and certain PPIs, particularly omeprazole and esomeprazole, which are known CYP2C19 inhibitors. Since clopidogrel is a prodrug requiring activation via CYP2C19, co-administration with PPIs may impair its antiplatelet efficacy and increase the risk of adverse cardiovascular events. Despite extensive debate, real-world evidence on this interaction remains conflicting, necessitating large-scale, population-based studies. This study investigates the clinical significance of clopidogrel–PPI co-administration in cardiovascular patients, focusing on outcomes such as myocardial infarction, stroke, stent thrombosis, and bleeding risk [6-10].

Discussion

The interaction between PPIs and clopidogrel has been extensively studied with mixed conclusions. Some observational studies and meta-analyses report a modest but statistically significant increase in cardiovascular events when clopidogrel is co-administered with PPIs, especially omeprazole. The hypothesized mechanism is the competitive inhibition of CYP2C19, which reduces the formation of clopidogrel's active metabolite, thereby weakening its platelet inhibition capacity. However, not all PPIs share the same degree of CYP2C19 inhibition. For instance, pantoprazole and rabeprazole exhibit minimal inhibitory effects and are considered safer alternatives. Clinical trials such as COGENT have provided reassuring results, showing no significant increase in adverse cardiovascular outcomes despite PPI use, although the trial was underpowered. Real-world data further complicate the picture, with many studies indicating that PPI use is often a marker for higher baseline risk rather than a direct contributor to poor outcomes. Furthermore, patient subgroups such as CYP2C19 poor metabolizers, the elderly, and those on additional medications may be more susceptible to clinically relevant interactions. It is also worth noting that the use of PPIs significantly reduces gastrointestinal bleeding events, which may offset any potential cardiovascular risks in certain populations. Given these complexities, clinical decision-making must balance both thrombotic and bleeding risks, ideally through personalized medicine approaches.

Conclusion

While the potential interaction between PPIs and clopidogrel continues to be a topic of debate, current evidence suggests that the clinical impact is modest and may vary depending on the type of PPI used and patient-specific risk factors. For high-risk patients, co-prescribing pantoprazole or other low-interaction PPIs remains a prudent strategy. Real-world studies offer valuable insights into these interactions outside controlled trial settings, but individual risk-benefit assessments remain essential. Future directions should include genotype-informed prescribing, especially in CYP2C19 poor metabolizers, and broader integration of clinical decision-support tools to guide safe co-administration practices. Ultimately, optimizing both gastrointestinal protection and antiplatelet efficacy requires a nuanced, patient-centered approach grounded in real-world evidence.

References

1. Li S, Zhang H, Chen K, Jin M, Vu S.H, et al. (2022. Drug Deliv 29: 1142-1149

,

1. Vlachopoulos A, Karlioti G, Balla E, Daniilidis V, Kalamas T, et al. (2022) Pharmaceutics 14: 359.

   , ,

2. Tibbitt MW, Dahlman JE, Langer R (2016) . J Am Chem Soc 138: 704-717.

   , ,

3. Builders PF, Arhewoh MI (2016) Starch-Stärke 10: 864-873.

   ,

4. Alshammari MK, Alshehri MM, Alshehri AM, Alshlali OM, Mahzari AM, et al. (2022) . J Drug Deliv Sci Technol 79: 104034.

   ,

5. Lai H, Liu S, Yan J, Xing F, Xiao P (2020) . ACS Sustain Chem Eng 8: 4941-4947.

   ,

6. Marco-Dufort B, Willi J, Vielba-Gomez F, Gatti F, Tibbitt MW. (2021) Biomacromolecules 22: 146-157.

   , ,

7. Smolensky MH, Peppas NA (2018) . Adv Drug Deliv Rev 10: 828-851.

   , ,

8. Jamieson LE, Byrne HJ (2017) Vib Spectrosc. 91: 16-30.

   ,

9. Mak KK, Pichika MR (2019) Drug Discov Today. 24: 773-780.

   , ,